Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reactogenicity of Novavax vs mRNA COVID-19 Vaccines
NCT07051031Phase 4Active, not recruiting
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19). Started Oct 2025; status: active, not recruiting.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07051031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051031.